Cellebrite (CLBT): CEO Shift and Guidance Cuts Contrast With Surging AI and FedRAMP Gains

On August 13, Cellebrite (NASDAQ: CLBT ) named a new chief executive and trimmed its full-year outlook on the same morning. Shiven Ramji stepped in as CEO effective that day, replacing Tom Hogan, while the company lowered its 2026 revenue and ARR targets after several large government deals slipped past the quarter. Management highlighted positive growth drivers during the call, including its first major FedRAMP contract for Guardian and early customer adoption for its newly launched AI platform, Genesis.

Underneath the disappointment, the underlying numbers still point up. Annual recurring revenue grew 21% year over year to $508 million, and revenue reached $131 million, up 16%, with subscription revenue making up 91% of that total. Gross margin was 86%, and adjusted EBITDA reached $31.8 million (a 24% margin). Cellebrite also raised its full-year adjusted EBITDA target to $153 million to $159 million.

Growth is also getting broader. Defense and intelligence ARR jumped 25%, and U.S. federal government growth accelerated into the mid-teens after sitting flat at the end of 2025. Asia Pacific was the standout region, growing 29%. The newer products are starting to matter too. Cellebrite closed its first major FedRAMP deal for Guardian with a long-standing US federal customer, an initial seven-figure order that was nearly 35 times the average annual spend of roughly $50,000 by a typical state or local agency. Genesis, a consumption-based AI product that launched June 10, 2026, pulled in about $400,000 in ARR within its first weeks and had already landed more than half a dozen customers by the end of the quarter, with trials expanding into the UK, Australia and Europe.

The reasons for the guidance cut are just as concrete. A handful of large transactions that management expected to close in the second quarter instead slipped beyond it, partly because of new administrative and procurement requirements tied to Cellebrite's foreign entity status with US federal and European government customers. At the same time, the shift toward the company's Insights product is not generating as much extra pricing and footprint expansion as expected, especially among US state and local government customers, where growth slowed to just below 20% from the mid-20% range a year earlier. Without newer product offerings such as Advanced Unlocks and Guardian Investigate, management said state and local government growth would have been in the mid-teens.

Those pressures pushed Cellebrite to lower its full-year 2026 ARR guidance to a range of $550 million to $560 million, a $15 million cut at the midpoint, and to reduce revenue guidance to $555 million to $561 million. The outlook also absorbs nearly three points of currency headwind from the Israeli shekel. On top of the numbers, the company is working through leadership turnover. Tom Hogan's exit as CEO, replaced by Shiven Ramji effective Aug. 13, 2026, comes as Cellebrite also searches for a permanent leader of its product and technology organization, with Iftach Smith running that group on an interim basis.

Hedge fund interest in Cellebrite ticked up from 35 funds to 36 heading into this report, a modest sign of accumulating conviction rather than a rush for the exits. Short sellers have taken a more skeptical stance, with 5.84% of the float sold short, enough to count as a real, if not extreme, bear camp forming. That combination suggests that the market is still sorting out whether the guidance cut is a one-time stumble or the start of a rougher stretch.

Cellebrite's second quarter leaves two stories running side by side. One shows a company still landing large government customers, expanding into AI-powered products, and generating enough cash to raise its own profitability targets. The other shows a company that missed its own numbers, cut its outlook, and is navigating a CEO change all at once. The trajectory for the second half of 2026 hinges on execution across new product rollouts, such as Genesis and Guardian, alongside the resolution of administrative procurement delays.

While we acknowledge the potential of CLBT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .